5-异噻唑甲胺,3-甲基-N-2-炔丙基<丙炔基>-(9CI) | 75549-83-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 5-异噻唑甲胺,3-甲基-N-2-炔丙基&lt丙炔基&gt-(9CI)
• 中文别名: N-(2,6-二甲基苯基)-2-吗啉-4-基乙酰胺
• 英文名称: 2-morpholin-2',6'-acetoxylidide
• 英文别名: N-(2,6-dimethyl-phenyl)-2-morpholin-4-yl-acetamide；Morlincain；N-(2,6-dimethylphenyl)-2-morpholin-4-ylacetamide
• CAS: 75549-83-6
• 化学式: C₁₄H₂₀N₂O₂
• 分子量: 248.325
• InChiKey: SOFDCJAETSXSQK-UHFFFAOYSA-N

物化性质

• 熔点：
  53-54 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  396.4±42.0 °C(Predicted)
• 密度：
  1.130±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] QUATERNARY AMMONIUM SALT COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] COMPOSÉ DE SEL D'AMMONIUM QUATERNAIRE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一种季铵盐类化合物及其制备方法与用途
  申请人：WEST CHINA HOSPITAL SICHUAN UNIV

  公开号：WO2020156359A1

  公开（公告）日：2020-08-06

  本发明公开了一种季铵盐类化合物及其制备方法与用途，属于化学医药领域。本发明提供了一种式Ⅰ所示的化合物、或其药学上可接受的盐、或其立体异构体、或其溶剂合物、或其前体药物、或其代谢产物。该化合物具有起效快，单次给药后具有长时间局部麻醉的效果，感觉神经阻滞时间大于运动神经阻滞时间，兼具长效局部麻醉作用和选择性局部麻醉作用，同时显著降低了具有表面活性剂结构特征的季铵盐化合物的副作用，具有良好的安全性，即本发明式Ⅰ化合物及其药学上可接受的盐，可用于制备安全的、具有长时间局部麻醉和选择性局部麻醉作用的药物，具有局部麻醉作用时间长、局部麻醉选择性好、安全性高的优点。
• Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease
  申请人：Martins Marco Aurelio

  公开号：US20080221206A1

  公开（公告）日：2008-09-11

  The present invention relates to lidocaine derived compounds, which present less anesthetic activity than lidocaine itself, but with more anti-inflammatory and spasmolytic activity than said lidocaine as well as pharmaceutical compositions with at least one of these compounds or a salt of those as active principle and to the use of such compositions to treat, prevent or inhibit atopic diseases including asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance. The pharmaceutical composition may be available in spray form, solution, suspension, emulsion destinated to be applied by nebulization, or in any of the pharmaceutical available forms for oral or injectable use.
• US8163803B2
  申请人：——

  公开号：US8163803B2

  公开（公告）日：2012-04-24
• [EN] SUBSTITUTED ACETANILIDES AND BENZAMIDES FOR THE TREATMENT OF ASTHMA AND PULMONARY INFLAMMATION<br/>[FR] ACETANILIDES ET BENZAMIDES SUBSTITUES UTILISES DANS LE TRAITEMENT DE L'ASTHME ET DES INFLAMMATIONS PULMONAIRES
  申请人：CORUS PHARMA

  公开号：WO2005025498A2

  公开（公告）日：2005-03-24

  Substituted acetanilide or benzamide compositions or formulations for delivery by aerosolization are described. The formulation contains an efficacious amount of acetanilide or benzamide compound able to inhibit inflammation in asthmatic lungs. Compounds of the invention are formulated in 5 ml solution of a quarter normal saline having pH between 5.0 and 7.0. The method for treatment of respiratory tract inflammation by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 µ, produced by nebulization or dry powder inhaler.